The alliance of CD133Pos and SOX-2 is suitable for therapeutics targeting glioblastoma because of the critical role it plays in GSCs maintenance, causing resistance to chemotherapy and radiotherapy [126]. This evidence concerns the gene SOX2 and glioblastoma.